Antidepressant Discontinuation Syndrome: Consensus Panel Recommendations for Clinical Management and Additional Research.
J Clin Psychiatry 2006;67(suppl 4):27-30
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Currently, no evidence-based guidelines exist for the management of serotonin reuptake
inhibitor (SRI) discontinuation syndrome. This article summarizes recommendations with respect
to future research as well as clinical management recommendations for SRI discontinuation syndrome.
Participants: In April 2004, a panel of physicians convened in New York City to discuss
recommendations for clinical management of and additional research on SRI discontinuation syndrome. Evidence: Previous guidance for management of SRI discontinuation syndrome was proposed
in 1997 in a consensus meeting also chaired by Alan F. Schatzberg. A literature search of the PubMed
database was conducted to identify articles on SRI discontinuation syndrome that have been published
Consensus Process: The 2004 panel reviewed important preclinical and clinical studies,
discussed prospective investigation of this syndrome in clinical trials, and suggested the establishment
of a research network to collect data in naturalistic settings. The panel also reviewed the management
recommendations published in 1997 and subsequently updated the recommendations, taking
into account the latest clinical data as well as the personal experience of its members with patients.
Additional preclinical and clinical studies are necessary to further elucidate the underlying
biological mechanisms of SRI discontinuation syndrome and to identify the patient populations
and agents that are most affected by this phenomenon. Management strategies include gradual tapering
of doses and should emphasize clinical monitoring and patient education.